Innate Pharma (IPHYF) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Innate Pharma (OTCMKTS:IPHYF) from a sell rating to a hold rating in a research note released on Thursday morning, reports.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

OTCMKTS:IPHYF remained flat at $$6.50 during trading hours on Thursday. Innate Pharma has a 12 month low of $5.07 and a 12 month high of $10.40. The firm has a market capitalization of $374.11 million, a PE ratio of 108.25 and a beta of 0.16.

About Innate Pharma

Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

Recommended Story: P/E Growth (PEG)

Get a free copy of the Zacks research report on Innate Pharma (IPHYF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with's FREE daily email newsletter.